SLC5A2 and diabetes mellitus: (2.2) Sodium-glucose-cotransporter 2 (SGLT2) inhibitors have efficiently been added to the usual antidiabetic therapy for adequate metabolic control in subjects with DM but also show a safe CV and nephro-protective profile (see Table 2).